Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
By Region : North America Europe APAC Latin America MEA Asia Pacific held a sizable revenue share in the global GLP-1 receptor agonist market and is set to witness substantial development by 2032, attributed to the rising prevalence of diabetes driven by factors, such as changing lifestyles, unhealthy diets, and sedentary habits, which is contributing to the increasing demand for effective diabetes management drugs
GLP-1 injections also slow down the emptying of the stomach, which helps prolong the sensation of fullness after eating
Back in 2025, researchers from the ATTAIN-1 trial found that taking orforglipron for 72 weeks was associated with significant benefits in patients with weight-related medical problems without diabetes
These results apply specifically to GLP-1 receptor agonists evaluated in randomized controlled trials and should not be extended to dual agonist therapies in the absence of dedicated long-term cancer outcome data
Its a system that produces results
